Auranofin inhibits the occurrence of colorectal cancer by promoting mTOR-dependent autophagy and inhibiting epithelial-mesenchymal transformation

• Published in: Anti-cancer drugs Vol. 35; no. 2; p. 129
• Main Authors: Zhang, Mei, Yang, Dong-Yuan, He, Zhi-Yi, Wu, Yu, Tian, Xiu-Yun, Huang, Qing-Yang, Ma, Wang-Bo, Deng, Min, Wang, Qi-Zhi, Yan, Shan-Jun, Zheng, Hai-Lun
• Format: Journal Article
• Language: English
• Published: England 01.02.2024
• Subjects: Animals; Auranofin - pharmacology; Auranofin - therapeutic use; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms - pathology; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Mice; TOR Serine-Threonine Kinases - metabolism
• ISSN: 1473-5741
• DOI: 10.1097/CAD.0000000000001540

Colorectal cancer (CRC) is one of the world's most common and deadly cancers. According to GLOBOCAN2020's global incidence rate and mortality estimates, CRC is the third main cause of cancer and the second leading cause of cancer-related deaths worldwide. The US Food and Drug Administration has approved auranofin for the treatment of rheumatoid arthritis. It is a gold-containing chemical that inhibits thioredoxin reductase. Auranofin has a number of biological activities, including anticancer activity, although it has not been researched extensively in CRC, and the mechanism of action on CRC cells is still unknown. The goal of this research was to see how Auranofin affected CRC cells in vivo and in vitro . The two chemical libraries were tested for drugs that make CRC cells more responsive. The CCK-8 technique was used to determine the cell survival rate. The invasion, migration, and proliferation of cells were assessed using a transwell test and a colony cloning experiment. An electron microscope was used to observe autophagosome formation. Western blotting was also used to determine the degree of expression of related proteins in cells. Auranofin's tumor-suppressing properties were further tested in a xenograft tumor model of human SW620 CRC cells. Auranofin dramatically reduced the occurrence of CRC by decreasing the proliferation, migration, and invasion of CRC cells, according to our findings. Through a mTOR-dependent mechanism, auranofin inhibits the epithelial-mesenchymal transition (EMT) and induces autophagy in CRC cells. Finally, in-vivo tests revealed that auranofin suppressed tumor growth in xenograft mice while causing no harm. In summary, auranofin suppresses CRC cell growth, invasion, and migration. Auranofin inhibits the occurrence and progression of CRC by decreasing EMT and inducing autophagy in CRC cells via a mTOR-dependent mechanism. These findings suggest that auranofin could be a potential chemotherapeutic medication for the treatment of human CRC.